Anthropic Details Drug Development Progress with Six Partners and Acquires Solo Biotech Mithril
Anthropic publishes specific lab metrics showing Claude's impact on drug design and regulatory filings, alongside the acquisition of a one-person muscular dystrophy treatment firm.
US-based artificial intelligence company Anthropic published a report on October 27, 2026, detailing early progress from its life sciences team's deep research partnerships with six organizations, including BigHat Biosciences and Bristol Myers Squibb, aimed at accelerating drug development. The company also announced the acquisition of Mithril Medicine, a one-person biotechnology firm focused on treating muscular dystrophy. Anthropic stated its strategy involves integrating AI into every stage of the process, from target identification to clinical trial management, to address distributed efficiency bottlenecks.
The report disclosed several specific laboratory-validated results. In cell therapy, Generate Biomedicines used Claude Code to redesign genetic instructions for CAR T-cell therapy. One new design was approximately 70% shorter than the standard version and, in lab tests, enabled immune cells to produce roughly 10 times as many receptors while killing tumor cells more efficiently. For antibody discovery targeting food allergies, Divergence Labs used Claude to autonomously generate about 35,000 designs. Early tests identified three designs capable of binding IgE and twenty capable of dislodging it, with three of the latter outperforming standard medications.
In lead optimization, BigHat Biosciences connected Claude to its automated lab system, Reccy, testing about 1,010 variants over ten weeks. By reanalyzing raw data and adjusting protocols, the best versions showed more than 10x tighter binding, an 18°C higher stability temperature for cancer-targeting leads, and a 100x slower clumping rate for long-lasting drug leads. Additionally, Enveda used Claude to review manufacturing documents, catching seven issues missed by human reviewers across 1,061 pages and reducing review time by 89%. Claude also drafted two key regulatory documents, with one taking four hours compared to the traditional three-month manual process.